Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes
Academic source · Molecular Pharmaceutics
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What the paper reports
Bispecific antibodies were used to bridge PEG motifs on LNPs and selected cellular surface markers without elaborate chemical conjugation. The platform enabled targeted mRNA delivery in cell models and transferrin-receptor-associated delivery in vivo. Researchers also measured endosomal responses at different antibody-loading ratios. Splenic enrichment supports further immune-cell targeting studies, but does not establish a clinical delivery solution.
Why this paper is included
Provides a modular targeting workflow for immune-cell delivery studies; receptor expression, antibody loading, and in vivo translation remain critical limitations.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections